Title |
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial
|
---|---|
Published in |
Experimental Hematology & Oncology, November 2014
|
DOI | 10.1186/2162-3619-3-26 |
Pubmed ID | |
Authors |
Teresa Moran, Enriqueta Felip, Vicki Keedy, Hossein Borghaei, Frances A Shepherd, Amelia Insa, Holly Brown, Timothy Fitzgerald, Sriram Sathyanarayanan, John F Reilly, David Mauro, Karl Hsu, Li Yan, David H Johnson |
Abstract |
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC).The phase I trial determined the recommended dose and safety of erlotinib plus dalotuzumab at 5 mg/kg or 10 mg/kg weekly in 20 patients. The phase II trial compared outcomes to erlotinib alone and erlotinib plus dalotuzumab at the mg/kg established in the phase I trial. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 28 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 18% |
Student > Doctoral Student | 4 | 14% |
Other | 3 | 11% |
Student > Bachelor | 3 | 11% |
Researcher | 2 | 7% |
Other | 4 | 14% |
Unknown | 7 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 36% |
Nursing and Health Professions | 4 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Unspecified | 1 | 4% |
Other | 3 | 11% |
Unknown | 8 | 29% |